参考文献 1. Pishvaian MJ. Individualizingtherapy for patients with pancreas cancer: 2. NCCN. Clinical PracticeGuidelines in Oncology. Pancreatic adenocarcinoma, version 1.2020. Accessed October6, 2020. https://bit.ly/2GDl7qW 3. Pishvaian MJ, Blais EM, BrodyJR, et al. Outcomes in patients with pancreatic adenocarcinoma with geneticmutations in dna damage response pathways: results from the know your tumorprogram. JCO Precis Oncol. Published online October 23, 2019.doi:10.1200/PO.19.00115 4. Kaufman B, Shapira-Frommer R,Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer anda germline BRCA1/2 mutation. J ClinOncol. 2015;20;33(3):244-250.doi:10.1200/JCO.2014.56.2728 5. Shroff RT, Hendifar A,McWilliams RR, et al. Rucaparib monotherapy in patients with pancreatic cancerand a known deleterious BRCA mutation. JCO PrecisOncol. Published online May 16, 2018.doi:10.1200/PO.17.00316 6. Golan T, Hammel P, Reni M, etal. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl JMed. 2019;25;381(4):317-327.doi:10.1056/NEJMoa1903387 7. Binder KAR, Mick R, O’Hara M,et al. A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitiveadvanced pancreatic cancer and a pathogenic germline or somatic mutationin BRCA1, BRCA2 or PALB2.Cancer Res. 2019;79(suppl13):CT234. doi:10.1158/1538-7445.AM2019-CT234 8. Brown LC, Sedhom R, SchwartzEB, et al. Association of LRP1B pathogenic genomic alterations with favorableoutcomes with immune checkpoint inhibitors across multiple tumor types. J ClinOncol. 2020;38(suppl 15):3007.doi:10.1200/JCO.2020.38.15_suppl.3007 9. Guan M, Bender RJ, PishvaianMJ, et al. Molecular and clinical characterization of BRAF mutations inpancreatic ductal adenocarcinomas (PDACs). J ClinOncol. 2018;36(suppl4):214. doi:10.1200/JCO.2018.36.4_suppl.214 10. Pishvaian MJ, Blais EM, BrodyJR, et al. Overall survival in patients with pancreatic cancer receivingmatched therapies following molecular profiling: a RETrospective analysis ofthe Know Your Tumor registry trial. LancetOncol. 2020;21(4):508-518.doi:10.1016/S1470-2045(20)30074-7DNA损伤修复
其他可诉性突变
与生物标志物检测同步进行
总结
highlighting data from ASCO and ESMO 2020. Slides presented at: 2020International Society of Gastrointestinal Oncology (ISGIO) Conference; October2-3, 2020; Virtual.